Press Release: TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic normalisationb at Week 44 compared with placebo.2,6,7,8,9
Press Release: TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease - Newscast
Tue, 29 Apr 2025 11:01:00 GMT Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and personalized care. ...
Fri, 25 Apr 2025 04:25:00 GMT Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the European Commission (EC) to treat adults with ulcerative colitis (UC).
Sun, 13 Apr 2025 17:00:00 GMT Tremfya is an interleukin-23 inhibitor ... rheumatology disease area leader at Johnson & Johnson Innovative Medicine, said in a press release. “These new topline data highlight the importance ...
Tue, 08 Apr 2025 17:00:00 GMT Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic arthritis (PsA). The APEX trial has been comparing the drug against placebo ...
Mon, 07 Apr 2025 17:00:00 GMT Guselkumab, an IL-23 inhibitor ... vice president and rheumatology disease area leader at Johnson & Johnson Innovative Medicine, said in a press release. "These new topline data highlight the ...
